Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.

Abstract

A phase II trial of spirogermanium was conducted in advanced previously untreated non-small cell lung cancer patients. The drug was given by intravenous infusion 3 times per week for 2 weeks, twice per week for the next 2 weeks, and then weekly. Starting dose was 125 mg/m2, and dose escalation of 25 mg/m2 per week was required in the absence of toxicity to a maximum dose of 200 mg/m2 per infusion. Fifteen eligible patients were treated, and no objective responses were seen. Primary toxicity was neurologic and reversible after withdrawal of the drug. We conclude that spirogermanium is not active against non-small cell lung cancer in the dosage used in this study.

• Authors: T E Lad, R R Blough, M Evrard, D P Shevrin, M A Cobleigh, C M Johnson, P Hange
• Journal: Investigational new drugs (Invest New Drugs) Vol. 7 Issue 2-3 Pg. 223-4 (Jul 1989) ISSN: 0167-6997 [Print] United States
• PMID: 2551841 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Organometallic Compounds
• Spiro Compounds
• spirogermanium

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Organometallic Compounds (adverse effects, therapeutic use)
• Spiro Compounds (adverse effects, therapeutic use)